Consumer goods giant Reckitt Benckiser has been permanently barred from displaying select ads for its Strepfen throat lozenges, as the Federal Court dismissed proceedings filed by rival iNova Pharmaceuticals.
A Federal Court judge has expressed her disbelief at a cross claim by generic drug maker Sandoz against Danish multinational H Lundbeck, as the court begins to weigh arguments over damages owed to Lundbeck in the long-running patent case over its blockbuster anti-depressant Lexapro.
Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world’s best-selling vaccine.
Shareholders in a class action against Sirtex have secured an order forcing the life sciences company to notify them of any plan that would see its $128 million in liquid assets drop below $80 million.
A judge has rejected an application by biotech company Sirtex Medical to limit a class action to shareholders who register as group members in the next month, saying a class-closure order could dramatically cut down on the size of the class.
HarperCollins has asked the Federal Court to toss a defamation case brought against it by two psychiatrists at the centre of the deep sleep therapy scandal that rocked the medical world in the 1960s and 70s, saying too much time had passed since the scandal.
An IVF clinic that pioneered the use of artificial intelligence for embryo selection has sued a rival clinic for allegedly copying an advertising campaign featuring the slogan “more chubby cheeks”.
A Victorian woman can undergo IVF treatment using donor sperm without the consent of her estranged husband, the Federal Court has ruled, finding a state law that forced her to get the OK from her spouse breached federal discrimination laws.
Generic drug makers Arrow and Apotex have won the ACCC’s blessing for a tie-up that will create the largest generic drug supplier in Australia, with the competition regulator saying the deal will not substantially lessen competition.
Shareholders in a class action against Sirtex Medical have lost a bid for an order preventing the life sciences company from quietly moving $128 million in cash assets out of the country after its $1.9 billion takeover by a Chinese private equity company comes into effect Thursday, but the battle over the money will likely continue.